Targeted therapies in breast cancer: are heart and vessels also being targeted?

Metzger‐Filho, Otto; Saini, Kamal S.; Castro, Gilberto de; Diaz, Marie; Gerche, André La; Azambuja, Evandro de; Piccart‐Gebhart, Martine

doi:10.1186/bcr3142

Cited by 25 publications

(19 citation statements)

References 111 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The incidence of hypertension rate was up to 35% with bevacizumab, a monoclonal antibody against VEGF-A [40,41]. Ultimately, considering the modest clinical benefit on the one hand, and the increase in toxicity on the other, the US Food and Drug Administration withdraw its approval of the breast cancer treatment for bevacizumab [42]. As mentioned above, EGCG is a drug of low toxicity, and significantly inhibits angiogenesis in breast tumor (under greater oxidative stress), but not in the normal tissues (no oxidative stress) such as the heart and limb muscles in the same mice.…”

Section: Discussionmentioning

confidence: 99%

EGCG, a major green tea catechin suppresses breast tumor angiogenesis and growth via inhibiting the activation of HIF-1α and NFκB, and VEGF expression

et al. 2013

View full text Add to dashboard Cite

The role of EGCG, a major green tea catechin in breast cancer therapy is poorly understood. The present study tests the hypothesis that EGCG can inhibit the activation of HIF-1α and NFκB, and VEGF expression, thereby suppressing tumor angiogenesis and breast cancer progression. Sixteen eight-wk-old female mice (C57BL/6 J) were inoculated with 10^6 E0771 (mouse breast cancer) cells in the left fourth mammary gland fat pad. Eight mice received EGCG at 50–100 mg/kg/d in drinking water for 4 weeks. 8 control mice received drinking water only. Tumor size was monitored using dial calipers. At the end of the experiment, blood samples, tumors, heart and limb muscles were collected for measuring VEGF expression using ELISA and capillary density (CD) using CD31 immunohistochemistry. EGCG treatment significantly reduced tumor weight over the control (0.37 ± 0.15 vs. 1.16 ± 0.30 g; P < 0.01), tumor CD (109 ± 20 vs. 156 ± 12 capillary #/mm^2; P < 0.01), tumor VEGF expression (45.72 ± 1.4 vs. 59.03 ± 3.8 pg/mg; P < 0.01), respectively. But, it has no effects on the body weight, heart weight, angiogenesis and VEGF expression in the heart and skeletal muscle of mice. EGCG at 50 μg/ml significantly inhibited the activation of HIF-1α and NFκB as well as VEGF expression in cultured E0771 cells, compared to the control, respectively. These findings support the hypothesis that EGCG, a major green tea catechin, directly targets both tumor cells and tumor vasculature, thereby inhibiting tumor growth, proliferation, migration, and angiogenesis of breast cancer, which is mediated by the inhibition of HIF-1α and NFκB activation as well as VEGF expression.

show abstract

Section: Discussionmentioning

confidence: 99%

EGCG, a major green tea catechin suppresses breast tumor angiogenesis and growth via inhibiting the activation of HIF-1α and NFκB, and VEGF expression

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Cardiac troponin is a medium-sized protein that regulates the cardiac contractile elements actin and myosin. The NT proBNP is useful for diagnosing cardiac failure in breathless patients but its utility for identifying subclinical cardiac pathology is unclear [ 77 ]. MoAbs should be discontinued for any severe ATE/VTE.…”

Section: Cardiovascular Aesmentioning

confidence: 99%

Adverse Events of Monoclonal Antibodies Used for Cancer Therapy

Guan

Zhou

et al. 2015

BioMed Research International

View full text Add to dashboard Cite

In 1997, the first monoclonal antibody (MoAb), the chimeric anti-CD20 molecule rituximab, was approved by the US Food and Drug administration for use in cancer patients. Since then, the panel of MoAbs that are approved by international regulatory agencies for the treatment of hematopoietic and solid malignancies has continued to expand, currently encompassing a stunning amount of 20 distinct molecules for 11 targets. We provide a brief scientific background on the use of MoAbs in cancer therapy, review all types of monoclonal antibodies-related adverse events (e.g., allergy, immune-related adverse events, cardiovascular adverse events, and pulmonary adverse events), and discuss the mechanism and treatment of adverse events.

show abstract

“…It is approved for the treatment of HER‐2 overexpressing breast cancer and HER‐2‐overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. Severe adverse effects include congestive heart failure and cardiac dysfunction, and there are cases of patients who have developed leukemia …”

Section: Ba Targeting or Mimicking Key Proteins (Cytokines Receptorsmentioning

confidence: 99%

“…Severe adverse effects include congestive heart failure and cardiac dysfunction, and there are cases of patients who have developed leukemia. 75 Pertuzumab is also a recombinant humanized mAb that is directed at the extracellular dimerization domain (subdomain II) of HER-2, and in so doing hinders the ligand-dependent heterodimerization of HER-2 with further HER family members, including EGFR, HER-3, and HER-4. 76 Pertuzumab is approved for metastatic breast cancer in combination with trastuzumab and conventional chemotherapy, but has an FDA warning for fetal toxicity.…”

Section: Malignant Diseasementioning

confidence: 99%

Orofacial adverse effects of biological agents

Georgakopoulou

Scully

2014

J of Invest & Clin Dent

View full text Add to dashboard Cite

Biological agents (BA) are increasingly used effectively in the treatment of a range of disorders, but to date, their application in diseases affecting the orofacial region has been fairly limited. Several orofacial adverse effects related to BA have been recently reported. However, the evidence for such adverse reactions is not always strong, and some of the adverse effects of BA have only been reported in case reports or case series. Most reactions to BA reported thus far have been in association with antitumor necrosis factor-α agents, which is not surprising, as these are the most widely-used BA. In the present study, the orofacial adverse effects are reported with various BA in order to sensitize clinicians to the possibilities. In addition, we briefly summarize the mode of action and indications of these BA. As the use and range of BA increases, the number and diversity of adverse effects might well increase. Despite the adverse effects of biological agents, these may often be less serious than the adverse effects of the more traditional immunosuppressive agents.

show abstract

Targeted therapies in breast cancer: are heart and vessels also being targeted?

Cited by 25 publications

References 111 publications

EGCG, a major green tea catechin suppresses breast tumor angiogenesis and growth via inhibiting the activation of HIF-1α and NFκB, and VEGF expression

EGCG, a major green tea catechin suppresses breast tumor angiogenesis and growth via inhibiting the activation of HIF-1α and NFκB, and VEGF expression

Adverse Events of Monoclonal Antibodies Used for Cancer Therapy

Orofacial adverse effects of biological agents

Contact Info

Product

Resources

About